Valuation: Novartis AG

Market Cap 274B 245B 228B 207B 390B 26,472B 393B 2,741B 1,071B 13,463B 1,027B 1,005B 43,280B P/E 2026 *
20.3x
P/E 2027 * 17x
Enterprise Value 305B 273B 254B 231B 435B 29,519B 438B 3,057B 1,194B 15,012B 1,146B 1,121B 48,261B EV / Sales 2026 *
5.28x
EV / Sales 2027 * 4.91x
Free-Float
91.66%
Yield 2026 *
3.01%
Yield 2027 * 3.14%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Compliance Officer 58 14/04/2025
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 274B
+2.70%+2.73%+40.91%+110.31% 1,060B
+1.44%-2.38%+36.83%+63.95% 623B
+1.75%+3.73%+16.55%+83.05% 480B
+0.60%-1.73%+62.98%+37.46% 352B
-1.69%+1.89%+22.07%+41.76% 345B
-1.02%+0.69%+11.62%+34.89% 274B
-1.12%-1.74%-5.59%+11.15% 249B
+2.60%-2.00%+39.77%+54.44% 223B
+1.82%-1.48%+25.75%+96.48% 182B
Average +0.21%-0.48%+27.88%+59.28% 420.89B
Weighted average by Cap. -0.05%+0.04%+31.52%+70.28%

Financials

2026 *2027 *
Net sales 57.78B 51.63B 48.17B 43.75B 82.4B 5,590B 83.02B 579B 226B 2,843B 217B 212B 9,139B 61.49B 54.94B 51.26B 46.56B 87.68B 5,948B 88.34B 616B 241B 3,025B 231B 226B 9,725B
Net income 14.47B 12.93B 12.07B 10.96B 20.64B 1,400B 20.8B 145B 56.65B 712B 54.34B 53.16B 2,289B 16.1B 14.38B 13.42B 12.19B 22.95B 1,557B 23.12B 161B 62.99B 792B 60.43B 59.12B 2,546B
Net Debt 31.49B 28.14B 26.25B 23.85B 44.91B 3,046B 45.24B 315B 123B 1,549B 118B 116B 4,981B 28.29B 25.28B 23.58B 21.42B 40.34B 2,737B 40.64B 283B 111B 1,392B 106B 104B 4,474B
Projected Income Statement - Annual - Novartis AG
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Novartis AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
143.98USD
Average target price
150.73USD
Spread / Average Target
+4.69%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Novartis AG